2026-01-23
Why Thalidomide Remains Unavoidable
Infectiology
By Ana Espino | Published on January 23, 2026 | 3 min read
Current standard treatments for leprosy rely on multidrug therapy. While effective against the infection itself, they do not prevent or adequately control immunological reactions, particularly ENL. Corticosteroids and clofazimine show only partial efficacy, often limited by relapses, adverse effects, or insufficient clinical response. The main challenges in disease management therefore lie in the rapid and sustained control of ENL, the prevention of neurological sequelae, and the reduction of long-term corticosteroid dependence.
In this context, this study was initiated to synthesize current clinical data on the use of thalidomide in the treatment of ENL, in order to assess its efficacy, mechanism of action, and limitations.
In this study, six controlled trials, 26 open-label studies, and one major longitudinal follow-up were selected, representing more than 6,000 patients treated for ENL. The studied populations mainly included patients with lepromatous or borderline lepromatous leprosy, often refractory to corticosteroid therapy.
The results show a rapid and dramatic clinical response to thalidomide, generally within less than one week, with significant improvement in cutaneous lesions, fever, pain, neuritis, and systemic manifestations. Response rates exceeded 90% in most studies, including in corticosteroid-resistant patients. Thalidomide also enabled a marked reduction in corticosteroid doses, representing a major clinical benefit.
From a mechanistic standpoint, its effect is anti-inflammatory, primarily related to modulation of TNF-α production by monocytes, although additional mechanisms are likely involved. Its efficacy is reproducible, durable, and independent of any antibacterial effect.
Leprosy remains a complex chronic disease, in which immunological reactions, particularly ENL, constitute a major cause of morbidity. The key challenges identified include the rapid control of inflammatory reactions, the prevention of neurological sequelae, and the limitation of prolonged corticosteroid therapy.
The objective of this study was to demonstrate the central role of thalidomide in the treatment of ENL. The findings confirm that thalidomide is the most effective treatment to date for moderate to severe ENL, providing a rapid, durable, and reproducible clinical benefit.
This strategy nevertheless presents major limitations, particularly the teratogenic risk, neurological adverse effects, and the need for strict control and contraception protocols, which restrict its use. Future research will focus on the development of alternative immunomodulatory agents, particularly targeting TNF-α or related inflammatory pathways, with the aim of achieving comparable efficacy and improved safety profiles.
Leprosy is a chronic infectious disease caused by Mycobacterium leprae, primarily affecting the skin and peripheral nerves. It is characterized by a clinical spectrum closely linked to the host immune response. Erythema nodosum leprosum (ENL) is one of the major complications of the disease. This type 2 inflammatory reaction, occurring in approximately 50% of patients with lepromatous forms, represents a major cause of morbidity, responsible for severe pain, systemic involvement, and irreversible neurological damage.
Current standard treatments for leprosy rely on multidrug therapy. While effective against the infection itself, they do not prevent or adequately control immunological reactions, particularly ENL. Corticosteroids and clofazimine show only partial efficacy, often limited by relapses, adverse effects, or insufficient clinical response. The main challenges in disease management therefore lie in the rapid and sustained control of ENL, the prevention of neurological sequelae, and the reduction of long-term corticosteroid dependence.
In this context, this study was initiated to synthesize current clinical data on the use of thalidomide in the treatment of ENL, in order to assess its efficacy, mechanism of action, and limitations.
Why Does No Treatment Perform Better Than Thalidomide?
In this study, six controlled trials, 26 open-label studies, and one major longitudinal follow-up were selected, representing more than 6,000 patients treated for ENL. The studied populations mainly included patients with lepromatous or borderline lepromatous leprosy, often refractory to corticosteroid therapy.
The results show a rapid and dramatic clinical response to thalidomide, generally within less than one week, with significant improvement in cutaneous lesions, fever, pain, neuritis, and systemic manifestations. Response rates exceeded 90% in most studies, including in corticosteroid-resistant patients. Thalidomide also enabled a marked reduction in corticosteroid doses, representing a major clinical benefit.
From a mechanistic standpoint, its effect is anti-inflammatory, primarily related to modulation of TNF-α production by monocytes, although additional mechanisms are likely involved. Its efficacy is reproducible, durable, and independent of any antibacterial effect.
Thalidomide: a Controlled Risk for a Major Benefit
Leprosy remains a complex chronic disease, in which immunological reactions, particularly ENL, constitute a major cause of morbidity. The key challenges identified include the rapid control of inflammatory reactions, the prevention of neurological sequelae, and the limitation of prolonged corticosteroid therapy.
The objective of this study was to demonstrate the central role of thalidomide in the treatment of ENL. The findings confirm that thalidomide is the most effective treatment to date for moderate to severe ENL, providing a rapid, durable, and reproducible clinical benefit.
This strategy nevertheless presents major limitations, particularly the teratogenic risk, neurological adverse effects, and the need for strict control and contraception protocols, which restrict its use. Future research will focus on the development of alternative immunomodulatory agents, particularly targeting TNF-α or related inflammatory pathways, with the aim of achieving comparable efficacy and improved safety profiles.
Read next: Leprosy: a disease still beyond control
About the author – Ana Espino
As
a scientific writer, Ana is passionate about bridging the gap between
research and real-world impact. With expertise in immunology, virology,
oncology, and clinical studies, she makes complex science clear and
accessible. Her mission: to accelerate knowledge sharing and empower
evidence-based decisions through impactful communication.
PhD in Immunology, specialized in Virology
Last press reviews
Obesity and heart failure: weight loss may restore heart muscle contractility
By Elodie Vaz | Published on April 30, 2026 | 4 min read<br><br>
Localized lung cancer: a new triplet therapy shows promising signs of efficacy
By Elodie Vaz | Published on April 29, 2026 | 4 min read<br>
Can stress during pregnancy erase the benefits of exercise ?
By Elodie Vaz | Published on April 29, 2026 | 4 min read<br>